Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What SUMICHEM guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 30 Oct 2026 | Sumitomo Chemical India filed the written transcript of its Q2 and H1 FY27 earnings call held on 27 October 2026. Management said Q2 FY27 revenue was INR 907 crore, down 2% year-on-year, and H1 FY27 revenue was INR 1,971 crore, down 1%; Q2 gross margin was 40.7% and EBITDA margin 20.5%. Management said H2 is... NSE copy | No results filed since | ||
| 26 Oct 2026 | Sumitomo Chemical India Ltd filed its investor presentation on financial results for the quarter and half-year ended 30 September 2026 (Q2FY27 and H1FY27). Q2FY27 revenue was Rs 907 crore, down 2% YoY; PAT was Rs 186 crore (down 15%); EBITDA was Rs 369 crore with a 20.5% margin (Q2FY26: 23.4%). H1FY27 revenue was... NSE copy | No results filed since | ||
| 27 Jul 2026 | Sumitomo Chemical India filed its investor presentation on results for the quarter ended 30 June 2026 (Q1FY27). Revenue rose 1% YoY to Rs 1,063 crore; EBITDA rose 6% to Rs 233 crore (margin 21.9%); reported PAT rose 20% to Rs 215 crore, including an exceptional insurance claim of Rs 26.9 crore. Management said the... NSE copy | -11.5 % | -2.4 % | -4.2 % |
| 04 Jun 2026 | Sumitomo Chemical India filed the written transcript of its Q4 and FY26 earnings call held on 28 May 2026. Management said FY26 PAT grew by more than 7% year-on-year to INR543 crores, with revenue up 3%, gross profit margin of 42%, EBITDA margin of 20.7% and net profit margin of 16.8%, all described as record... NSE copy | +20.5 % | +0.6 % | -1.9 % |
| 27 May 2026 | Investor presentation on the financial results for the quarter and year ended 31 March 2026, filed under Regulation 30. Q4FY26 revenue Rs. 684 crore (up 1% YoY); Q4FY26 PAT Rs. 134 crore (up 12% YoY), PAT margin 19.6% (Q4FY25: 17.6%)... see note below. FY26 revenue Rs. 3,238 crore (up 3% YoY); FY26 PAT Rs. 543... NSE copy | +20.5 % | +0.6 % | -1.9 % |
| 03 Nov 2025 | Sumitomo Chemical India filed the written transcript of its Q2 and H1 FY26 earnings call held on 28 October 2025. Management said Q2 consolidated revenue was INR930 crores versus INR988 crores a year earlier, with the decline attributed to weather-driven volume contraction; Q2 PAT was INR178 crores versus INR193... NSE copy | -13.0 % | -11.5 % | -0.7 % |
| 03 Jun 2025 | Filed the written transcript dated 28 May 2025 of Sumitomo Chemical India's Q4 and FY'25 earnings call, held on 28 May 2025 (filed 3 June 2025). Management said FY'25 revenue grew 11% year-on-year, EBITDA grew 33% and PAT grew 37%, with EBITDA margin at 20.1% (up 339 bps) and net profit margin at 16.1% (up 308... NSE copy | +40.8 % | +26.0 % | -0.8 % |
| 27 May 2025 | Investor presentation on financial results for the quarter and year ended 31 March 2025 (Q4FY25 and FY25). FY25 revenue was Rs 3,149 crore, up 11% from Rs 2,844 crore in FY24; FY25 PAT was Rs 632 crore, up 33% from Rs 475 crore; FY25 EBITDA was Rs 1,290 crore, up 21%. Q4FY25 revenue was Rs 679 crore, up 1% from... NSE copy | +40.8 % | +26.0 % | -0.8 % |
| 27 Jan 2025 | Sumitomo Chemical India Ltd filed an investor presentation on its financial results for the quarter and nine months ended 31 December 2024 (Q3FY25 and 9MFY25). Q3FY25 revenue was Rs 642 crore, up 18% from Rs 542 crore in Q3FY24; Q3FY25 PAT was Rs 106 crore, up 61% from Rs 66 crore, and gross margin was 42.1% versus... NSE copy | +40.8 % | +26.0 % | -0.8 % |
Filings tagged as guidance, newest first (9 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 30 Oct 2026 | Management change | Sumitomo Chemical India filed the written transcript of its Q2 and H1 FY27 earnings call held on 27 October 2026. Management said Q2 FY27 revenue was INR 907 crore, down 2% year-on-year, and H1 FY27 revenue was INR 1,971 crore, down 1%; Q2 gross margin was 40.7% and EBITDA margin 20.5%. Management said H2 is... NSE copy |
| 27 Jul 2026 | Management change | Sumitomo Chemical India filed its investor presentation on results for the quarter ended 30 June 2026 (Q1FY27). Revenue rose 1% YoY to Rs 1,063 crore; EBITDA rose 6% to Rs 233 crore (margin 21.9%); reported PAT rose 20% to Rs 215 crore, including an exceptional insurance claim of Rs 26.9 crore. Management said the... NSE copy |
| 04 Jun 2026 | Management change | Sumitomo Chemical India filed the written transcript of its Q4 and FY26 earnings call held on 28 May 2026. Management said FY26 PAT grew by more than 7% year-on-year to INR543 crores, with revenue up 3%, gross profit margin of 42%, EBITDA margin of 20.7% and net profit margin of 16.8%, all described as record... NSE copy |
| 27 May 2026 | Management change | Investor presentation on the financial results for the quarter and year ended 31 March 2026, filed under Regulation 30. Q4FY26 revenue Rs. 684 crore (up 1% YoY); Q4FY26 PAT Rs. 134 crore (up 12% YoY), PAT margin 19.6% (Q4FY25: 17.6%)... see note below. FY26 revenue Rs. 3,238 crore (up 3% YoY); FY26 PAT Rs. 543... NSE copy |
| 29 Apr 2026 | Credit rating | Sumitomo Chemical India Ltd filed an intimation under Regulation 30 of SEBI LODR dated 29 April 2026. CRISIL Limited has reaffirmed the credit rating on the company's bank loan facilities. Total bank loan facilities rated: ₹200 crore. Long-term rating reaffirmed at CRISIL AA/Stable. NSE copy |
| 27 Jan 2026 | Legal or regulatory | Sumitomo Chemical India filed its investor presentation on results for the quarter and nine months ended 31 December 2025 (Q3FY26 and 9MFY26). Q3FY26 revenue from operations was Rs 568 crore, down 12% YoY from Rs 642 crore; PAT was Rs 99 crore? No, PAT was Rs 76 crore (Q3FY25: Rs 87 crore), down 13% YoY including a... NSE copy |
| 04 Mar 2025 | Legal or regulatory | Sumitomo Chemical India filed unaudited standalone results for the quarter and nine months ended 31 December 2024, approved by the Board on 27 January 2025, with a limited review report from BSR & Co. LLP. Q3 FY25 revenue from operations was ₹6,224.29 million versus ₹5,404.49 million in the year-ago quarter; Q3... NSE copy |
| 03 Feb 2025 | Credit rating | Sumitomo Chemical India Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, dated 3 February 2025. CRISIL Limited has reaffirmed the credit rating on the Company's bank loan facilities. Total bank loan facilities rated: ₹ 200 Crore. Long-term rating: CRISIL AA/Stable. NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (8 in all). A list of what was filed, not a judgement of the company.